Trump, Novartis and Drug Prices
Trump admin defends IRA drug price negotiation program in Novartis lawsuit
The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug price negotiation program enacted under President Joe Biden. | The Trump administration is adopting a similar legal framework as the Biden administration regarding the drug price negotiation program,
Trump administration defends Medicare drug price talks in case brought by Novartis
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate prescription drug prices, a sign that some consumer advocates said suggests the Trump administration is willing to maintain the controversial program.
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...
Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...
Prior to this announcement, Novartis' dividend was comfortably covered by both cash flow and earnings. This indicates that ...
According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.
Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...
Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...
Novartis Indias NEST competition culminates in a showcase of innovative healthcare solutions, highlighting the talent of young entrepreneurs.
Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with ...
Swiss pharma giant Novartis is taking legal action against the Australian cancer care provider as a dispute over how to fund ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback